Pharmacology
Do amygdala astrocytes help or hurt chronic neuropathic pain?
Open access · cc by · source: Europe PMC
CeA GFAP rose at 4 weeks (not 1 week) after SNL; inhibiting astrocytes with FCA increased CeLC excitability and facilitated mechanical/affective pain behaviors, suggesting beneficial astrocyte roles.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Inspect source passages
Do amygdala astrocytes help or hurt chronic neuropathic pain?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
GFAP increased at 4 weeks post-SNL, not at 1 week.
Glial fibrillary acidic protein (GFAP, astrocytic marker) immunoreactivity and mRNA expression were increased at the chronic (4 weeks post-SNL), but not acute (1 week post-SNL), stage of neuropathic pain.
Slice FCA used at 100 µM for 1 hour.
Pre-incubation of brain slices with FCA (100 µM, 1 h), increased excitability through altered hyperpolarization-activated current (I h ) functions, without significantly affecting synaptic responses at the PB-CeLC synapse.
Key findings
Astrocyte markers increased chronically (4 weeks post-SNL). Slice FCA (100 µM, 1 h) raised excitability via Ih changes without major PB-CeLC synaptic shifts. Intra-CeA FCA facilitated mechanical withdrawal and evoked vocalizations; GFAP (not NeuN) fell, supporting selective astrocyte inhibition.
Methodology
Measured CeA GFAP protein/mRNA after spinal nerve ligation, then used fluorocitric acid (FCA) in CeLC slices and intra-CeA injections to test effects on excitability, PB-CeLC synapses, and pain-like behaviors in chronic neuropathic rats.
Limitations
Rodent SNL findings may not translate directly to human chronic pain therapies; FCA is a tool compound, not a clinical drug.
Related papers in this topic
Same topic cluster — not a recommendation engine.